Neurotech Reports Announces First European Leaders Forum

January 30, 2025 04:00 AM PST | By Send2Press

Neurotech Reports Announces First European Leaders Forum — Image source: Send2Press

Recent News

UK banks hit with £100M penalty for breaching gilt trading rules

How Does Diamondback Energy (NASDAQ:FANG) Maintain Its Market Position

Will US companies return to Russia as market conditions shift?

Forget Trump, bet on Musk: decoding the market’s new favourite play

SAN FRANCISCO, Calif., Jan. 30, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the longest-serving publishing and market intelligence firm covering the neuromodulation industry, announced the launch of its first European management and investment conference. The two-day event, called Neurotech Leaders Forum at imec, will take place on June 3-4, 2025 on the campus of imec in Leuven, Belgium. Imec, a world-leading research and innovation center in nanoelectronics and digital technologies, is deeply committed to advancing health innovations through the power of semiconductor technologies, making it the ideal host for the conference.

Image caption: Tim Denison will keynote the first European Neurotech Leaders Forum on June 3-4, 2025 at imec in Leuven, Belgium.

Tim Denison, Ph.D. FREng, co-founder of Amber Therapeutics, will keynote the conference. Denison also holds a joint appointment in engineering science and clinical neurosciences at Oxford University, where he explores the fundamentals of physiologic closed-loop systems. Prior to that, he was a technical fellow at Medtronic plc and vice president of research & core technology for the Restorative Therapies Group, where he helped oversee the design of next generation neural interface and algorithm technologies for the treatment of chronic neurological disease.

At the conference, Neurotech Reports editor James Cavuoto will offer an update on the state of the European neuromodulation industry. Neurotech Reports editors JoJo Platt, Jeremy Koff, and Victor Pikov will moderate sessions devoted to peripheral nerve stimulation, bioelectronic medicine applications, venture capital investment, and regulatory and reimbursement issues affecting neurotech startups and emerging firms. Imec executives Peter Peumans, Paru Deshpande, and Barun Dutta (who conceived of, and led the Neuropixels program at imec since its inception) will also offer updates on technology advances at the European research and innovation center.

Executives from several emerging neurotechnology startups, including Italian firm WISE srl and German firm Precisis, will also present at the conference during multiple entrepreneur panels. In addition to imec, sponsors of the conference include Cirtec Medical, MST, Valtronic, and Osypka.

Neurotech Reports will also produce the 8th Annual Bioelectronic Medicine Forum on April 10, 2025 in New York City, and the 25th Annual Neurotech Leaders Forum San Francisco, on November 5-6, 2025.

For more information, contact Neurotech Reports at 415 546 1259 or visit: https://neurotechreports.com/pages/leadersforum-europe.html.

MULTIMEDIA:

Image link for media: https://www.Send2Press.com/300dpi/25-0130-s2p-ntrep-timdenison-300dpi.jpg

Image caption: Tim Denison will keynote the first European Neurotech Leaders Forum on June 3-4, 2025 at imec in Leuven, Belgium.

News Source: Neurotech Reports

To view the original post, visit: https://www.send2press.com/wire/neurotech-reports-announces-first-european-leaders-forum/.

This press release was issued by Send2Press® Newswire on behalf of the news source, who is solely responsible for its accuracy. www.send2press.com.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.